FDA's May 2026 Fragrance Allergen Rule Deadline Passed With No Rule Published — The Silence Is the Signal

According to the FDA's own Unified Regulatory Agenda, a proposed rule on 'Disclosure of Fragrance Allergens in Cosmetic Labeling' (RIN 0910-AI90) was targeted for publication in May 2026, under MoCRA Section 609(b). The rule would require cosmetic manufacturers to identify specific fragrance allergens on product labels, ending the longstanding practice of aggregating them under 'fragrance' or 'parfum'. As of 21 May 2026, the rule has not been published in the Federal Register. The original deadline under MoCRA was June 29, 2024 — nearly two years ago. It was rescheduled to January 2025, then May 2026, now overdue.

The silence is doing structural work. MoCRA mandated two outstanding proposed rules: fragrance allergen labeling, and Good Manufacturing Practice (GMP). The Unified Agenda now classifies GMP as a 'Long-Term Action' with no scheduled date. Crowell & Moring noted in April 2026 that 'primary compliance costs for the fragrance allergen rule are expected to centre on label reformulation across affected product lines' — a significant operational implication for every brand currently labeling 'fragrance' as a single ingredient.

The asymmetry is the real signal. Every day the FDA rule is delayed, US brands continue to label 'fragrance' or 'parfum' without individual allergen disclosure, while EU brands face the 82-allergen disclosure requirement binding on 31 July 2026 (covered in earlier briefs). A brand selling into both EU and US markets must maintain two documentation systems — one with granular allergen disclosure, one without. When the FDA rule does publish, the comment period opens, and the subsequent finalisation timeline will compress what is normally a 2–3 year reformulation cycle into whatever runway remains.

The brands most exposed are those that have marketed on 'clean fragrance' without granular allergen documentation. For them, the FDA's silence is not protection — it's a countdown. The supplier-side play (see the Turpaz / Phoenix consolidation note from 17 May) is already pricing this in: full allergen documentation is becoming a procurement requirement, and the fragrance houses that can deliver it at scale will hold the pricing power when the rule lands.